<p>The US Food and Drug Administration on Thursday approved the emergency use of Eli Lilly and Co's arthritis drug, baricitinib, in combination with Gilead Sciences Inc's remdesivir, to treat Covid-19 patients.</p>.<p>Baricitinib, sold under the brand name of Olumiant, is an FDA-approved oral medication to treat moderately-to-severely active rheumatoid arthritis.</p>.<p><a href="https://www.deccanherald.com/coronavirus-live-news-covid-19-latest-updates.html" target="_blank"><strong>CORONAVIRUS SPECIAL COVERAGE ONLY ON DH</strong></a></p>.<p>In a clinical trial of hospitalised patients with Covid-19, baricitinib along with remdesivir was shown to reduce time to recovery to within 29 days after starting treatment compared to patients who received a placebo with remdesivir.</p>.<p>The health regulator approved the drug in combination with remdesivir for treating suspected or laboratory-confirmed Covid-19 in hospitalised adults and children two years of age or older requiring oxygen support. </p>
<p>The US Food and Drug Administration on Thursday approved the emergency use of Eli Lilly and Co's arthritis drug, baricitinib, in combination with Gilead Sciences Inc's remdesivir, to treat Covid-19 patients.</p>.<p>Baricitinib, sold under the brand name of Olumiant, is an FDA-approved oral medication to treat moderately-to-severely active rheumatoid arthritis.</p>.<p><a href="https://www.deccanherald.com/coronavirus-live-news-covid-19-latest-updates.html" target="_blank"><strong>CORONAVIRUS SPECIAL COVERAGE ONLY ON DH</strong></a></p>.<p>In a clinical trial of hospitalised patients with Covid-19, baricitinib along with remdesivir was shown to reduce time to recovery to within 29 days after starting treatment compared to patients who received a placebo with remdesivir.</p>.<p>The health regulator approved the drug in combination with remdesivir for treating suspected or laboratory-confirmed Covid-19 in hospitalised adults and children two years of age or older requiring oxygen support. </p>